Celltrion is strengthening its market influence in Oceania by continuing to expand market share for its cancer drugs and autoimmune disease treatments in Australia and New Zealand.
According to Celltrion and drug market research firm IQVIA on the 10th, as of the third quarter of last year, the breast and stomach cancer biosimilar "Herzuma" (ingredient trastuzumab) recorded a 56% market share in Australia.
In Australia, Herzuma achieved a result that exceeded the combined share of all other trastuzumab products, including the original.
The autoimmune disease treatments "Remsima" (ingredient Infliximab) and "Remsima SC" (subcutaneous formulation) recorded a combined 58% share in Australia.
Launched in Australia in 2021, Remsima SC increased its share to 29% as of the third quarter of last year from about 5% in 2022, marking an average annual growth rate of about 80% over three years.
The high-margin new product "Steqeyma" (ingredient ustekinumab) posted a 12% share in just one quarter of sales, showing steep growth.
Australia has implemented policies favorable to biosimilars, which worked positively to expand prescriptions for Celltrion products. The local subsidiary has pursued tailored sales and marketing strategies that reflect market characteristics.
In neighboring New Zealand, "Herzuma" recorded a market share close to 100%. "Vegzelma" (ingredient bevacizumab) is also maintaining a competitive edge with an 81% share.
This was analyzed as being mainly due to Celltrion's New Zealand subsidiary maintaining smooth communication with the government procurement agency (Pharmac), consistently winning bids, and thereby expanding market share.
Celltrion plans to sequentially launch high-margin new products such as "Stoboclo-Ossenbelt" (ingredient denosumab) to strengthen marketing synergy.
Kim Ji-tae, Celltrion's head of South Asia, said, "Based on locally tailored sales strategies and an expanded product portfolio, we will strengthen our marketing capabilities, improve patient access to care, and do our best to ensure sustainable growth."